Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Chronic glomerular diseases, associated with renal failure and cardiovascular morbidity, represent a major health issue. However, they remain poorly understood. Here we have reported that tightly controlled mTOR activity was crucial to maintaining glomerular podocyte function, while dysregulation of mTOR facilitated glomerular diseases. Genetic deletion of mTOR complex 1 (mTORC1) in mouse podocytes induced proteinuria and progressive glomerulosclerosis. Furthermore, simultaneous deletion of both mTORC1 and mTORC2 from mouse podocytes aggravated the glomerular lesions, revealing the importance of both mTOR complexes for podocyte homeostasis. In contrast, increased mTOR activity accompanied human diabetic nephropathy, characterized by early glomerular hypertrophy and hyperfiltration. Curtailing mTORC1 signaling in mice by genetically reducing mTORC1 copy number in podocytes prevented glomerulosclerosis and significantly ameliorated the progression of glomerular disease in diabetic nephropathy. These results demonstrate the requirement for tightly balanced mTOR activity in podocyte homeostasis and suggest that mTOR inhibition can protect podocytes and prevent progressive diabetic nephropathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gödel et al. [16] suggested that mTOR signaling plays a role in podocyte homeostasis.”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [16]
In the citing paper
“The decrease in activity of neurofibromin in NF1 might also be associated with LPG which is a glomerular disease, and contribute to the development of LPG as an additional factor.”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [16]
In the citing paper
“Although podocytes have high basal levels of autophagy, high mTORC1 activity is also required for these cells to maintain their function”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [51]
In the citing paper
“However, the side effects of long-term or complete mTORC1 inhibition in kidney cells have been well-recognized, such as the early onset of proteinuria caused by specific inhibition of mTORC1 activity in podocytes in mice and the disruption of kidney tubular homeostasis caused by specific inhibition of mTORC1 activity in kidney tubular cells in mice51,80.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [51]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Self-citationA global double-fluorescent Cre reporter mouse
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007) · genesis · doi:10.1002/dvg.20335 · Cited by 3,491
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
VEGF Inhibition and Renal Thrombotic Microangiopathy
Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707330 · Cited by 1,504
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Research works printed but not linked: 5
- Estacio, 2001, Adv Intern Med., 46, 359
- Munivenkatappa, 2010, Histol Histopathol., 25, 189
- Weening, 1987, Am J Pathol., 129, 64
- Artacho-Perula, 1993, Lab Invest., 68, 56
- Souster, 1980, J Anat., 130, 595
Cited by
Items 301–400 of 553
Immune-mediated entities of (primary) focal segmental glomerulosclerosis
Braun, F., Homeyer, I. C., Alachkar, N., & Huber, T. B. (2021) · Cell and Tissue Research · doi:10.1007/s00441-021-03454-3 · Cited by 30
Self-citationThe Role of the Epidermal Growth Factor Receptor in Diabetic Kidney Disease
Harris, R. C. (2022) · Cells · doi:10.3390/cells11213416 · Cited by 25
“mTOR activity increases in podocytes in diabetic mice, and correlates with increased ER stress and progressive glomerulosclerosis [35].”
BackgroundImpaired Leukocytes Autophagy in Chronic Kidney Disease Patients
Chen, W., Hung, K., Wen, M., Hsu, P.-Y., Chen, T., Wang, H., Fang, J., Shie, S., & Wang, C. (2013) · Cardiorenal Medicine · doi:10.1159/000356212 · Cited by 26
Han, X., Li, Q., Wang, C., & Li, Y. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0630-0173 · Cited by 29
Hudkins, K. L., Wietecha, T., Steegh, F., & Alpers, C. E. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00498.2019 · Cited by 26
Kim, K., Hong, G.-L., Jung, D.-Y., Karunasagara, S., Jeong, W., & Jung, J. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00285-4 · Cited by 29
Rangel, É. B., Gomes, S. A., Kanashiro‐Takeuchi, R. M., Saltzman, R., Wei, C., Ruiz, P., Reiser, J., & Hare, J. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-33082-x · Cited by 26
Amin, N. G., Rahim, A. A., Rohoma, K. H., Elwafa, R. A., Dabees, H. M. F., & Elrahmany, S. M. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01450-5 · Cited by 26
“Additionally, several pathways have been suggested previously for the early prevention of DKD focusing on the pivotal role of mTOR through rapamycin treatment [28] or reducing the number of mTORC1 copies in podocytes [29, 30].”
BackgroundAlharbi, Y. M., Bima, A. I. H., & Elsamanoudy, A. Z. (2021) · Journal of Microscopy and Ultrastructure · doi:10.4103/jmau.jmau_33_20 · Cited by 27
“Nutrient deficiency primarily induces autophagy by inhibiting mTORC1.[62,63]”
BackgroundActivation of acetyl-CoA synthetase 2 mediates kidney injury in diabetic nephropathy
Lu, J., Li, X. Q., Chen, P. P., Zhang, J. X., Liu, L., Wang, G. H., Liu, X. Q., Jiang, T. T., Wang, M. Y., Liu, W. T., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.165817 · Cited by 27
“Podocytes were pretreated with OSS_128167, a selective inhibitor that increases H3K9 acetylation, and then we treated podocytes with HG. Significant decreases in mRNA expression of raptor induced by ACSS2 inhibitor were reversed by OSS_128167 (Figure 7E).”
Tao, J., Polumbo, C., Reidy, K. J., Sweetwyne, M. T., & Suszták, K. (2013) · Kidney International · doi:10.1038/ki.2013.463 · Cited by 28
Niclosamide ethanolamine improves kidney injury in db/db mice
Han, P., Zhan, H., Shao, M., Wang, W., Song, G., Yu, X., Zhang, C., Ge, N., Yi, T., Li, S., et al. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.08.003 · Cited by 24
Mechanism of progression of diabetic kidney disease mediated by podocyte mitochondrial injury
Su, J., Ye, D., Gao, C., Huang, Q., & Gui, D. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05749-0 · Cited by 28
Zhang, Y. (2021) · Bioscience Reports · doi:10.1042/bsr20203131 · Cited by 24
“Podocyte hypertrophy(29), apoptosis(30), and EMT(31) are the main causes of”
Redox regulation in diabetic kidney disease
Daehn, I. S., Ekperikpe, U. S., & Stadler, K. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00047.2023 · Cited by 24
Mechanisms and implications of podocyte autophagy in chronic kidney disease
Njeim, R., Merscher, S., & Fornoni, A. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00415.2023 · Cited by 23
Self-citationCunard, R. A. (2013) · Scientifica · doi:10.1155/2013/750871 · Cited by 27
“Both knockdown and overexpression of mTORC1 in podocytes cause proteinuria in animal models, and human diabetic kidney disease has been associated with enhanced mTORC1 function [214].”
BackgroundADCK4 “reenergizes” nephrotic syndrome
Málaga-Diéguez, L., & Suszták, K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73168 · Cited by 24
Associations between structural and functional changes to the kidney in diabetic humans and mice
Powell, D. W., Kenagy, D. N., Zheng, S., Coventry, S. C., Xu, J., Cai, L., Carlson, E. C., & Epstein, P. N. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.06.016 · Cited by 26
“Homeostatic pathways of the podocyte regulated by insulin (Welsh et al., 2010) and mTOR (Godel et al., 2011, Inoki et al., 2011) are disrupted by diabetes and genetic manipulations of these pathways in mouse podocytes mimic DN.”
BackgroundSestrin2 Signaling Pathway Regulates Podocyte Biology and Protects against Diabetic Nephropathy
Ala, M. (2023) · Journal of Diabetes Research · doi:10.1155/2023/8776878 · Cited by 25
“Podocytespecific genetic inhibition of mTORC1 hyperactivation by heterozygous knockout of Raptor prevented mesangial matrix accumulation and glomerulosclerosis in diabetic mice (Figure 2) [135].”
BackgroundInfluentialTian, J., Wang, Y., Guo, H., & Li, R. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.08.004 · Cited by 22
Yuanlin, P., & Dehai, Y. (2018) · 中医杂志:英文版 · doi:10.1016/s0254-6272(18)30921-x · Cited by 22
Das, F., Maity, S., Ghosh‐Choudhury, N., Kasinath, B. S., & Choudhury, G. G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.007023 · Cited by 22
“Deacetylation of S6 kinase in the glomeruli of streptozotocin-induced diabetic rats We and others have reported previously that activation of mTORC1 increased the phosphorylation of S6 kinase in diabetic mice and human kidney (13,14,16,17,41-43).”
BackgroundDiabetes complications and extracellular vesicle therapy
Soltani, S., Mansouri, K., Parvaneh, S., Thakor, A. S., Pociot, F., & Yarani, R. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09680-y · Cited by 22
“Activation of mTOR signaling in DN patients suggests that mTOR might mediate podocyte autophagy dysfunction [106].”
BackgroundNiclosamide ethanolamine improves diabetes and diabetic kidney disease in mice.
Han, P., Shao, M., Guo, L., Wang, W., Song, G., Yu, X., Zhang, C., Ge, N., Yi, T., Li, S., et al. (2018) · Europe PMC (PubMed Central) · Cited by 24
mTOR in podocyte function: Is rapamycin good for diabetic nephropathy?
Lu, M.-K., Gong, X., & Guan, K. (2011) · Cell Cycle · doi:10.4161/cc.10.20.17686 · Cited by 22
Mou, X., Shah, J., Bhattacharya, R., Kalejaiye, T. D., Sun, B., Hsu, P., & Musah, S. (2022) · Bioengineering · doi:10.3390/bioengineering9050188 · Cited by 25
“Studies aimed at understanding the onset and progression of kidney diseases have been conducted by using animal models and immortalized podocyte cell lines [4,5].”
BackgroundIndependent role of PP2A and mTORc1 in palmitate induced podocyte death
Kumar, S., & Tikoo, K. (2015) · Biochimie · doi:10.1016/j.biochi.2015.02.009 · Cited by 21
Peres, G. B., Schor, N., & Michelacci, Y. M. C. D. S. (2017) · Biochimie · doi:10.1016/j.biochi.2017.02.004 · Cited by 22
Long Noncoding RNAs and Their Therapeutic Promise in Diabetic Nephropathy
Coellar, J. D., Long, J., & Danesh, F. R. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000515422 · Cited by 22
Emerging Functions of Autophagy in Kidney Transplantation
Pallet, N., Livingston, M. J., & Dong, Z. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12533 · Cited by 23
“There is actually no direct evidence that autophagy promotes these side effects, but given the importance of mTOR and autophagy in podocyte responses to stress in one hand (33,34), and in regulating immune responses on the other hand (35,36), one can imagine that autophagy mediated by pharmacological mTOR inhibition i…”
BackgroundYao, Y., Wang, J., Yoshida, S., Nada, S., Okada, M., & Inoki, K. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015010032 · Cited by 22
Self-citationmTOR pathway: A key player in diabetic nephropathy progression and therapeutic targets
Shi, J., Liu, X., Jiao, Y., Tian, J., An, J., Zou, G., & Zhuo, L. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101260 · Cited by 30
Xue, R., Zhai, R., Xie, L., Zheng, Z., Jian, G., Chen, T., Su, J., Gao, C., Wang, N., Yang, X., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/9309768 · Cited by 22
“Previous study provided evidence for mTOR’s novel function on podocyte apoptosis in DKD [5], and mTOR inhibition could protect against podocyte apoptosis and delay the progression of DKD [28].”
BackgroundLipotoxicity, Nutrient-Sensing Signals, and Autophagy in Diabetic Nephropathy
Kume, S., & Maegawa, H. (2020) · JMA Journal · doi:10.31662/jmaj.2020-0005 · Cited by 24
“Although mTORC1 is physiologically essential for cell growth, differentiation, protein translation, and inhibition of autophagy, its hyper-activation was recently reported to be strongly associated with pathogenesis of diabetic podocytopathy (60), (61), ((62)).”
BackgroundFetal Reprogramming of Nutrient Surplus Signaling, O-GlcNAcylation, and the Evolution of CKD
Packer, M. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000177 · Cited by 19
Ketone Body Metabolism in Diabetic Kidney Disease
Yamahara, K., Yasuda‒Yamahara, M., Kuwagata, S., Chin‒Kanasaki, M., & Kume, S. (2024) · Kidney360 · doi:10.34067/kid.0000000000000359 · Cited by 19
“19,22,23 Ketone body administration with 1,3-butanediol has been studied in a type 2 diabetic model, db/db mice.”
BackgroundConnexin 43‑autophagy loop in the podocyte injury of diabetic nephropathy
Ji, J., Zhao, Y., Chen, N., Yang, M., Zhu, X., Shi, H., Gan, W., & Zhang, A. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4335 · Cited by 19
“It was observed that mTOR signaling was activated after stimulation with HG in vivo and in vitro, indicating that an mTOR‐dependent mechanism may be involved in Cx43‐mediated podocyte injury in DN, which is consistent with previous results (31,32).”
ResultDas, F., Bera, A., Ghosh‐Choudhury, N., Sataranatarajan, K., Kamat, A., Kasinath, B. S., & Choudhury, G. G. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110072 · Cited by 21
Clark, S. D., Song, W., Cianciolo, R. E., Lees, G. E., Nabity, M. B., & Liu, S. (2018) · Veterinary Pathology · doi:10.1177/0300985818806050 · Cited by 19
“These findings have been demonstrated in mice with diabetic nephropathy, CKD using a doxycycline-inducible transgenic system, and Alport mice using anti-miR-21 oligonucleotide therapy.(17,22,23,32) Tubular epithelial cells depend primarily on fatty acid oxidation (FAO) as a source of energy.”
BackgroundSelf-citationGu, T.-T., Zhang, D., Wan, Z.-Y., Li, T., Jiao, R., Chen, T., Zhao, X., & Kong, L. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111079 · Cited by 20
Autophagy: a novel therapeutic target for kidney diseases
Kume, S., Uzu, T., Maegawa, H., & Koya, D. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0695-2 · Cited by 18
“mentioned earlier are present in glomerular epithelial cells, and are reportedly associated with the regulation of cellular function in glomerular epithelial cells [17–19].”
BackgroundMammalian target of rapamycin complex 1 activation in podocytes promotes cellular crescent formation
Mao, J., Zeng, Z., Xu, Z., Li, J., Jiang, L., Fang, Y., Xu, X., Hu, Z., He, W., Yang, J., et al. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00018.2014 · Cited by 18
“Abnormal activation of mTORC1 participates in the pathogenesis of many types of kidney disease, including polycystic kidney disease, diabetic nephropathy (12, 18, 22, 25), podocyte dysfunction, glomerular sclerosis, and kidney fibrosis (4, 10, 11, 14, 15, 27, 30).”
BackgroundDas, F., Ghosh‐Choudhury, N., Lee, D. Y., Gorin, Y. C., Kasinath, B. S., & Choudhury, G. G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207285 · Cited by 20
Regulation of the Homeostatic Unfolded Protein Response in Diabetic Nephropathy
Wang, H., Karnati, S., & Madhusudhan, T. (2022) · Pharmaceuticals · doi:10.3390/ph15040401 · Cited by 19
“DN is associated with the abnormal activation of the mTOR complex (mTORC1), a kinase that senses nutrient availability in podocytes [67,68].”
BackgroundBioenergetics: the evolutionary basis of progressive kidney disease
Chevalier, R. L. (2023) · Physiological Reviews · doi:10.1152/physrev.00029.2022 · Cited by 19
Mesangial Cell Mammalian Target of Rapamycin Complex 1 Activation Results in Mesangial Expansion
Nagai, K., Tominaga, T., Ueda, S., Shibata, E., Tamaki, M., Matsuura, M., Kishi, S., Murakami, T., Moriya, T., Abe, H., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016111196 · Cited by 17
C1-Ten is a PTPase of nephrin, regulating podocyte hypertrophy through mTORC1 activation
Lee, J., Koh, A., Jeong, H., Kim, E., Ha, T., Saleem, M. A., & Ryu, S. H. (2017) · Scientific Reports · doi:10.1038/s41598-017-12382-8 · Cited by 17
Role of mTOR signaling in the regulation of high glucose‑induced podocyte injury
Li, Q., Zeng, Y., Jiang, Q. Y., Wu, C., & Zhou, J. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7236 · Cited by 18
“A previous study revealed that inhibition of mTORC1 signaling activity prevented glomerulosclerosis and significantly ameliorates the progression of glomerular disease in DN (47), and inhibition of mTORC2 signaling activity reduced HG‐induced podocyte apoptosis and attenuated albuminuria (48).”
BackgroundLegáz, I., Bernardo, M. V., Alfaro, R., Martínez‐Banaclocha, H., Galián, J. A., Jiménez-Coll, V., Boix, F., Mrowiec, A., Salmerón, D., Botella, C., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.547849 · Cited by 18
State of the art – sirtuin 1 in kidney pathology – clinical relevance
Bielach-Bazyluk, A., Małyszko, J., Hryszko, T., & Zbroch, E. (2019) · Advances in Medical Sciences · doi:10.1016/j.advms.2019.04.005 · Cited by 17
The intelligent podocyte: sensing and responding to a complex microenvironment
Bertram, J. F., Cullen‐McEwen, L. A., Andrade‐Oliveira, V., & Câmara, N. O. S. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00965-y · Cited by 18
“Abnormal mTORC1 activation has also been linked to podocyte loss, GBM thickening, mesangial expansion and proteinuria in people with DKD and mouse models of DKD 118 (Fig.”
Akt2 relaxes podocytes in chronic kidney disease
Reiser, J. (2013) · Nature Medicine · doi:10.1038/nm.3357 · Cited by 16
mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats
Nistala, R., Raja, A., & Pulakat, L. (2017) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2016-0567 · Cited by 17
The role of extracellular vesicles in podocyte autophagy in kidney disease
Sun, B.-C., Zhai, S.-B., Zhang, L., & Sun, G. (2021) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-020-00594-z · Cited by 18
Targeting signaling pathways in glomerular diseases
Hénique, C., & Tharaux, P. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328354a598 · Cited by 16
mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions
Fernandes-Silva, G., de Paula, M. I., & Rangel, É. B. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1239708 · Cited by 18
“Genetic deletion of mTORC1 in mouse podocyte leads to proteinuria and progressive glomerulosclerosis [39].”
BackgroundInfluentialMaity, S., Bera, A., Ghosh‐Choudhury, N., Das, F., Kasinath, B. S., & Choudhury, G. G. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.01.021 · Cited by 16
“Also, loss of mTORC1 as well as mTORC2 in the glomerular cells leads to significant renal injury with albuminuria [36,38].”
BackgroundThe mystery of the ketogenic diet: benevolent pseudo-diabetes
Blagosklonny, M. V. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1644765 · Cited by 18
Rac1 in podocytes promotes glomerular repair and limits the formation of sclerosis
Asao, R., Seki, T., Takagi, M., Yamada, H., Kodama, F., Hosoe-Nagai, Y., Tanaka, E., Trejo, J. A. O., Nonaka, K., Sasaki, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23278-6 · Cited by 16
Lu, Q., Hu, X., Hou, Q., Yu, L., Cao, K., Ding, D., Lu, Y., & Dai, C. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111451 · Cited by 17
Ji, B., Liu, J., Yin, Y., Xu, H. M., Shen, Q., & Yu, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06124-0 · Cited by 15
Drug discovery in focal and segmental glomerulosclerosis
Pullen, N., & Fornoni, A. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.058 · Cited by 14
Self-citationLive or Let Die: Is There any Cell Death in Podocytes?
Braun, F., Becker, J. U., & Brinkkoetter, P. T. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.03.008 · Cited by 19
Fohlen, B., Tavernier, Q., Huynh, T. M., Caradeuc, C., Corre, D. L., Bertho, G., Cholley, B., & Pallet, N. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.12.023 · Cited by 15
“In line with this, the activation of other adaptive molecular pathways, such as the mammalian target of rapamycin complexes (MTORC) 1- and 2-mediated signaling pathways, are beneficial in patients with kidney injuries (Canaud et al., 2013; Godel et al., 2011; Inoki et al., 2011), although non-invasive markers of their…”
BackgroundLi, F., Mao, X., Zhuang, Q., Zhao, Z., Zhang, Z., & Wu, H. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1480-x · Cited by 15
Chen, J., Li, H., Zhuo, J., Lin, Z., Hu, Z., He, C., Wu, X., Jin, Y., Lin, Z., Su, R., et al. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0267 · Cited by 18
Loss of genome maintenance is linked to mTOR complex 1 signaling and accelerates podocyte damage
Braun, F., Mandel, A. M., Blomberg, L., Wong, M. N., Chatzinikolaou, G., Meyer, D. H., Reinelt, A., Nair, V., Akbar-Haase, R., McCown, P. J., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.172370 · Cited by 13
“Podocyte damage and loss have been shown to be tightly linked to mTORC1 activation and cellular hypertrophy of the remaining podocytes (10, 24, 43).”
Self-citationmTOR-Dependent Autophagy Regulates Slit Diaphragm Density in Podocyte-like Drosophila Nephrocytes
Spitz, D., Comas, M., Gerstner, L., Kayser, S., Helmstädter, M., Walz, G., & Hermle, T. F. (2022) · Cells · doi:10.3390/cells11132103 · Cited by 13
“Genetic deletion of mTORC1 in mice entailed foot process effacement in podocytes [13], and treatment with mTOR inhibitors causes or aggravates proteinuria dose-dependently in about 10% of renal transplant recipients [42].”
BackgroundSelf-citationARF6 mediates nephrin tyrosine phosphorylation-induced podocyte cellular dynamics
Lin, J. S., Jeon, J. S., Fan, Q., Wong, H. N., Palmer, M. B., & Holzman, L. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184575 · Cited by 14
Sato, S., Norikura, T., Mukai, Y., Yamaoka, S., & Mikame, K. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.108977 · Cited by 13
Role of mTOR Signaling for Tubular Function and Disease
Grahammer, F., Huber, T. B., & Artunç, F. (2021) · Physiology · doi:10.1152/physiol.00021.2021 · Cited by 14
Self-citationNew Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences
Popović, L., & Bulum, T. (2025) · Diagnostics · doi:10.3390/diagnostics15030284 · Cited by 17
Podocyte-specific deletion of miR-146a increases podocyte injury and diabetic kidney disease
Li, X., Venkatesh, I., Villanueva, V., Wei, H., Geraghty, T., Rajagopalan, A. R., Helmuth, R., Altintas, M. M., Faridi, H. M., & Gupta, V. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.897188 · Cited by 14
“mice according to published protocols (18, 25).”
MethodKunke, M., Knöfler, H., Dahlke, E., Rodriguez, L. Z., Böttner, M., Larionov, A. A., Saudenova, M., Ohrenschall, G. M., Westermann, M., Porubský, Š., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06074-7 · Cited by 14
Mechanism of Regulation of Big-Conductance Ca2+-Activated K+ Channels by mTOR Complex 2 in Podocytes
Wang, Y., Tao, J., Wang, M., Yang, L., Ning, F., Xin, H., Xu, X., Cai, H., Zhang, W., Yu, K., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00167 · Cited by 13
“Although the role of mTORC2 in renal diseases still needs clarification, increasing evidence has implicated mTORC2 in podocyte functions (Godel et al., 2011; Canaud et al., 2013; Eid et al., 2016; Zhang et al., 2016).”
BackgroundSasaki, H., Takahashi, Y., Ogawa, T., Hiura, K., Nakano, K., Sugiyama, M., Okamura, T., & Sasaki, N. (2019) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.19-0101 · Cited by 12
“On the other hand, decreased mTOrC1 activity also induces podocyte dysfunction after birth [5].”
BackgroundTranslational Aspects of the Mammalian Target of Rapamycin Complexes in Diabetic Nephropathy
Daher, A. A., Alkhansa, S., Azar, W. S., Rafeh, R. W., Ghadieh, H. E., & Eid, A. A. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0217 · Cited by 13
“As compared with WT diabetic mice, diabetic Raptor Het podocyte mice displayed a significant decrease in proteinuria, lower glomerulosclerosis scores, and reduced mesangial matrix expansion (38).”
InfluentialAfshinnia, F., Vega-Warner, V., & Killen, P. (2013) · Clinical Kidney Journal · doi:10.1093/ckj/sft010 · Cited by 12
“by additional deletion of mTORC2, while significant activation of mTORC1 subsequent to induction of diabetes was associated with subsequent hypertrophy of podocyte, foot process effacement and eventual detachment from glomerular basement membrane, suggesting a major role for mTOR signaling in podocyte homeostasis [21].”
BackgroundPodocyte-specific knockout of cyclooxygenase 2 exacerbates diabetic kidney disease
Wang, L., Sha, Y., Bai, J., Eisner, W., Sparks, M. A., Buckley, A. F., & Spurney, R. F. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00614.2016 · Cited by 13
“Third, KO of COX2 is dependent on the ability of the podocin promoter to promote Cre-mediated recombination, which is likely incomplete (11).”
BackgroundCrosstalk between the mTOR pathway and primary cilia in human diseases
Prosseda, P. P., Prosseda, S. D., Tran, M., Liton, P. B., & Sun, Y. (2023) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2023.09.004 · Cited by 13
Liebau, M. C. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00068 · Cited by 12
Sestrin2 in diabetes and diabetic complications
Zhang, X., Luo, Z., Li, J., Lin, Y., Yu, L., & Li, W. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1274686 · Cited by 12
The pivotal role of glucose transporter 1 in diabetic kidney disease
Zhang, L., Wu, M., Zhang, J., Liu, T., Fu, S., Wang, Y., & Xu, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122932 · Cited by 13
Turinsky, L., Rehrl, S., Nguyen, C., Benyahia, S., Kuperwasser, N., Vasseur, F., Arevalo, A. R., Rabant, M., Goudin, N., Mesnard, L., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq7825 · Cited by 11
Autophagy: a two-edged sword in diabetes mellitus
Yamamoto, S., Kazama, J. J., & Fukagawa, M. (2013) · Biochemical Journal · doi:10.1042/bj20131282 · Cited by 12
Alshaman, R., Truong, L. D., & Oyekan, A. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12648 · Cited by 12
“These results are underscored by studies in which podocyte-specific interruption of mTORC1 function leads to glomerular disease and proteinuria.(26) However, in several animal studies, rapamycin did not affect normal kidney function, hemodynamics or histopathology.”
ResultInsulin secretion impairment induced by rosuvastatin partly though autophagy in INS‐1E cells
Qian, L.-L., Zhu, K., Lin, Y., An, L., Huang, F., Yao, Y., & Ren, L. (2019) · Cell Biology International · doi:10.1002/cbin.11208 · Cited by 11
“C) levels (Gödel et al., 2011).”
REDD1 Ablation Attenuates the Development of Renal Complications in Diabetic Mice
Sunilkumar, S., Yerlikaya, E. I., Toro, A. L., Miller, W. P., Chen, H., Hu, K., Kimball, S. R., & Dennis, M. D. (2022) · Diabetes · doi:10.2337/db22-0402 · Cited by 12
“In support of the prior report (57), we observed enhanced phosphorylation of rpS6 in the kidney of STZ diabetic mice, which is consistent with activation of mTORC1.”
BackgroundThe role of mechanistic target of rapamycin in maintenance of glomerular epithelial cells
Yao, Y., & Inoki, K. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000181 · Cited by 12
“All rights rese It is noteworthy that complete ablation of mTORC1 activity in podocytes in podo-Raptor knockout mice leads to early onset of proteinuria [11,12].”
BackgroundInfluentialSelf-citationProhibitin Signaling at the Kidney Filtration Barrier
Ising, C., & Brinkkoetter, P. T. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55330-6_29 · Cited by 12
Maezawa, Y., Cina, D., & Quaggin, S. E. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381462-3.00022-7 · Cited by 13
mTORC1 signaling and diabetic kidney disease
Swaroop, V., Ozkan, E. E., Herrmann, L., Thurman, A., Kopasz-Gemmen, O., Kunamneni, A., & Inoki, K. (2024) · Diabetology International · doi:10.1007/s13340-024-00738-1 · Cited by 10
“In fact, mTORC1 activity monitored by the phosphorylated form of S6 protein (pS240/244 S6) is largely elevated in the podocytes and tubular cells in both type 1 and type 2 diabetic animals and individuals with type 2 diabetes [7, 8].”
Self-citationLiu, K., Yang, Q., Lang, Y., Zou, Y., Yuan, J., Yang, J., Ma, J., Cai, L., Kong, X., Yang, F., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70140 · Cited by 10
Ding, F., Zhang, X., Li, X., Zhang, Y., Li, B., & Ding, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112972 · Cited by 10
“Gödel et al indicated that mTORC2 was essential for podocyte development and maintenance in diabetic nephropathy [32], and Canaud et al found that AKT2 activation by mTORC2 was required for podocyte survival in nephron reduction-induced renal disease [33].”
Backgroundvan der Wolde, J. W., Haruhara, K., Puelles, V. G., Nikolic‐Paterson, D. J., Bertram, J. F., & Cullen‐McEwen, L. A. (2022) · Cell and Tissue Research · doi:10.1007/s00441-022-03611-2 · Cited by 12
Koya, D., Kitada, M., Kume, S., & Kanasaki, K. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0908-3 · Cited by 10
“However, podocyte-specific Raptor-heterozygous mice show partial deletion of mTORC1 activity in podocyte and resistance to the development of diabetic nephropathy in both streptozotocin-induced type 1 diabetic mice [26] and type 2 diabetic db/db mice [27].”
BackgroundInfluentialKuczkowski, A., & Brinkkoetter, P. T. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2619-7 · Cited by 11
“including focal-segmental glomerulosclerosis already evident 8 weeks after birth (Gödel et al. 2011).”
BackgroundInfluentialIwata, W., Unoki‐Kubota, H., Kato, H., Shimizu, A., Matsumoto, M., Imasawa, T., Igarashi, A., Matsumoto, K., Noda, T., Terauchi, Y., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229397 · Cited by 11
“Additionally, podocyte-specific Tsc1 knockout mice show features of diabetic nephropathy and mTORC1 hyperactivation is present in podocytes of patients with diabetic nephropathy [27, 28].”
BackgroundPolycystic Kidney Disease: ADPKD and ARPKD
Liebau, M. C., & Bergmann, C. (2016) · Springer eBooks · doi:10.1007/978-3-662-52972-0_12 · Cited by 11
Metadata
- Authors
- Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., Wiech, T., Fornoni, A., Nelson, R. G., Kretzler, M., Wanke, R., Pavenstädt, H., Kerjaschki, D., Cohen, C. D., Hall, M. N., Rüegg, M. A., Inoki, K., Walz, G., & Huber, T. B.
- Affiliations
- University of Freiburg (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of Zurich (CH)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) (DE)
- University of Miami (US)
- National Institutes of Health (US)
- University of Münster (DE)
- Medical University of Vienna (AT)
- University of Basel (CH)
- Life Sciences Institute (SG)
- Corresponding author
- Huber, Tobias B.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-06-01
- Volume
- 121
- Issue
- 6
- Pages
- 2197-2209
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3104746
- OpenAlex
- W2051719011
- Cited by
- 547
- References
- 62
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 28 · 2023: 36 · 2022: 30 · 2021: 43 · 2020: 50 · 2019: 39 · 2018: 40 · 2017: 34 · 2016: 38 · 2015: 36 · 2014: 40 · 2013: 47 · 2012: 25
- FWCI
- 31.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (122439)
- National Institutes of Health (5r01dk083491-09)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK083491, P30DK081943, DK-083491, R01DK124709)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- mTOR, mTORC1, mTORC2, podocytes, diabetic nephropathy, glomerulosclerosis, proteinuria, glomerular hypertrophy, hyperfiltration, mTOR inhibition, glomerular disease, gene deletion
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Regulatory-Associated Protein of mTOR, Rapamycin-Insensitive Companion of mTOR Protein, Adult, Animals, Carrier Proteins, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Humans, Kidney Glomerulus, Mice, Inbred C57BL, Mice, Inbred ICR, Mice, Transgenic, Nephrosis, Lipoid, Proteins, Proteinuria, Transcription Factors, Trans-Activators, Mice, Knockout, Disease Progression, Gene Dosage, Genetic Predisposition to Disease, Sirolimus, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, Podocytes, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.